Snowball Research

Snowball Research

Heron Therapeutics (HRTX) appoints new CEO with a history of selling companies; brought on board via settlement with activist investors; Kevin Kotler of Broadfin Capital joins the Board

Apr 26, 2024
∙ Paid
Share

Heron Therapeutics (HRTX)
807KB ∙ PDF file
Download
Download

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Snowball Research | March Intelligence Research LLP
Publisher Terms
Substack
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture